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DNA methylation in interleukin-11 predicts clinical response to
antidepressants in GENDEP
TR Powell1, RG Smith1, S Hackinger1, LC Schalkwyk1, R Uher1,2, P McGuffin1, J Mill1,3 and KE Tansey1
Transcriptional differences in interleukin-11 (IL11) after antidepressant treatment have been found to correspond to clinical
response in major depressive disorder (MDD) patients. Expression differences were partly mediated by a single-nucleotide
polymorphism (rs1126757), identiﬁed as a predictor of antidepressant response as part of a genome-wide association study. Here
we attempt to identify whether DNA methylation, another baseline factor known to affect transcription factor binding, might also
predict antidepressant response, using samples collected from the Genome-based Therapeutic Drugs for Depression project
(GENDEP). DNA samples from 113 MDD individuals from the GENDEP project, who were treated with either escitalopram (n¼ 80) or
nortriptyline (n¼ 33) for 12 weeks, were randomly selected. Percentage change in Montgomery–Åsberg Depression Rating Scale
scores between baseline and week 12 were utilized as our measure of antidepressant response. The Sequenom EpiTYPER platform
was used to assess DNA methylation across the only CpG island located in the IL11 gene. Regression analyses were then used to
explore the relationship between CpG unit methylation and antidepressant response. We identiﬁed a CpG unit predictor of general
antidepressant response, a drug by CpG unit interaction predictor of response, and a CpG unit by rs1126757 interaction predictor of
antidepressant response. The current study is the ﬁrst to investigate the potential utility of pharmaco-epigenetic biomarkers for the
prediction of antidepressant response. Our results suggest that DNA methylation in IL11 might be useful in identifying those
patients likely to respond to antidepressants, and if so, the best drug suited to each individual.
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INTRODUCTION
Major depressive disorder (MDD) is predicted to be the second
leading cause of disability by 2020.1 Antidepressants are currently
the ﬁrst line of treatment for MDD, but around two-thirds of
patients fail to respond to the ﬁrst antidepressant prescribed, and
a third fail to respond to multiple antidepressant treatments.2
Studies have attempted to establish biomarkers to predict res-
ponse to antidepressant medication and to personalize treatment.
Genetic biomarkers have been investigated as predictors of
clinical outcome; however, results from large-scale pharmaco-
genetic studies have mostly been unsuccessful in identifying
genes that are robustly associated with clinical antidepressant
response.3–7
However, recent evidence draws further support to results from
one genome-wide association study performed in the Genome-
based Therapeutic Drugs for Depression project (GENDEP), which
identiﬁed a single-nucleotide polymorphism (SNP) (rs1126757) in
interleukin-11 (IL11) that predicted response to the selective
serotonin reuptake inhibitor escitalopram.4 Further investigation
of IL11 at the transcriptional level found it to be expressed
at a lower level in responders compared with that in non-
responders after treatment with escitalopram, but not before the
initiation of escitalopram treatment.8 Gene expression differences
after treatment were partially mediated by rs1126757, implicating
rs1126757 as a treatment-emergent expression quantitative
trait locus.8
Similarly to expression quantitative trait loci, DNA methylation
can also affect transcription factor binding and moderate gene
expression changes, and DNA methylation has been linked to the
pathophysiology of mood disorders.9,10 Subsequently, in this
study we aimed to investigate whether baseline DNA methylation
in IL11 could be used to predict antidepressant response.
The current study used blood samples collected from 113
individuals diagnosed with MDD as part of the GENDEP project.
We attempted to identify: (1) whether there are DNA methylation
predictors of general antidepressant response (independent of
drug or genotype); (2) whether there are differential DNA
methylation predictors, which could be used to predict whether
an individual is more likely to respond to the antidepressant
escitalopram or nortriptyline; and (3) whether there is an
interaction between rs1126757 genotype and DNA methylation,
which predicts response to antidepressants.
MATERIALS AND METHODS
Clinical sample
Patient samples were taken from the GENDEP project, which has been
described in detail elsewhere.11 Brieﬂy, GENDEP is a 12-week, partially
randomized, open-label pharmacogenetic study with two active treatment
arms. A total of 868 treatment-seeking adults (men: n¼ 321; women:
n¼ 547) with MDD of at least moderate severity according to the ICD-10 or
DSM-IV criteria were recruited from 9 European centers. Patients were
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aged 19–72 years and were of Caucasian European parentage. Diagnoses
were established using the semi-structured Schedules for Clinical
Assessment in Neuropsychiatry interview.12 Exclusion criteria were
personal and family history of schizophrenia or bipolar disorder, current
substance dependence, or whether participants had previously taken both
of the drugs and demonstrated treatment resistance. Eligible participants
were allocated to treatment with either the selective serotonin reuptake
inhibitor escitalopram (total n¼ 394) or the noradrenaline reuptake
inhibitor nortriptyline (total n¼ 312), which differed by antidepressant
mechanisms of action.13 Patients with no contraindications were randomly
allocated to a ﬂexible-dosage of nortriptyline (50–150mg daily) or escitalo-
pram (10–30mg daily) for 12 weeks. Patients with contraindications for
one drug were offered the other. The GENDEP project was approved by
ethics boards of participating centers, and all participants provided a
written consent after the procedures were explained. GENDEP is registered
at EudraCT (No.2004-001723-38, https://eudract.ema.europa.eu/) and
ISRCTN (No. 03693000, http://www.controlled-trials.com).
Participants were assessed for severity of depressive symptoms by using
the clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS)
on a weekly basis.14 Previous work found that the MADRS scores were the
most sensitive, clinically representative and internally consistent scores for
depression symptom changes in GENDEP, and, consequently, is the
measure we use in this study.15
A subset of 113 individuals (males n¼ 46; females n¼ 67; age 40.3
years±11.7 years) were randomly selected among patient samples, who
had complete clinical data for the full 12 weeks of treatment and had
genome-wide association study genotype data. All patients had a
diagnosis of moderate to severe MDD, with a baseline severity of
27.7±4.8 (average MADRS score, s.d.). Individuals were treated with either
the antidepressant escitalopram (n¼ 80) or nortriptyline (n¼ 33). Fewer
than 10% of individuals had previously taken an antidepressant on
entering GENDEP and all individuals were drug-free for 2 weeks before the
start of the study. Before this, patients had reported taking antidepressants
(n¼ 10), benzodiazepines (n¼ 35) and hypnotics (n¼ 14). The average
duration of the current depressive episode in our sample was 21.3±19.3
weeks (average duration, s.d.). Seventy-two of our patients had experi-
enced a stressful life event within 6 months before entering the
GENDEP study, as measured using the List of Threatening Experiences
Questionnaire.16 Percentage change in the MADRS score from baseline to
week 12 was used as a measure of antidepressant response. Higher
positive changes in the percentage MADRS represent better treatment
response.
Experimental details
Genotyping. Patient blood samples were collected and stored in
ethylenediaminetetraacetic acid (EDTA), after which DNA was extracted
using a standard extraction procedure.17 Genotype data were collected as
part of a genome-wide association study.4 Full details of genotyping and
quality-control measures can be found elsewhere.4 Brieﬂy, samples were
sent to the Centre National de Genotypage (Evry, France) and were
genotyped using the Illumina Human 610-Quad BeadChips (Illumina, San
Diego, CA, USA), which genotypes more than 600 000 SNPs. All 113
patients included in the current study passed the routine quality-control
tests, which included removing individuals for ambiguous sex, abnormal
heterozygosity, cryptic relatedness (up to third-degree relatives),
genotyping incompleteness (o97% coverage) and non-white European
admixture. Genotype data include the rs1126757 SNP. Genotype data for
this SNP was extracted using PLINK.18
DNA methylation. All DNA samples were quantiﬁed and tested for purity
using the Nanodrop ND1000 (Thermo Scientiﬁc, Wilmington, DE, USA).
Previous quality-control measures were employed for the purpose of
genotyping and DNA had been stored at  80 1C.
Four hundred nanograms of genomic DNA was treated with sodium
bisulﬁte using the EZ-96 DNA Methylation Kit (Zymo Research, Irvine, CA,
USA) following the standard manufacturer’s protocol. IL11 primer design was
based on in-silico bisulﬁte-amplicon prediction using the Mass array package
(Bioconductor, www.bioconductor.org) in R (http://www.R-project.org).
Primers were designed to span the CpG island in IL11 (chr 19: 55880511–
55880989, Genome Reference Consortium GRCh37/USCS version hg19,
University of California Santa Cruz Genome Browser). Forward primers
consisted of the following sequence: 50-GATGGAGTTGGAGG
TTTTAAGTTTTA-30 . Reverse primers consisted of the following sequence
50-ACCCATAACTCTACCCCTCTCC-30 . For each 10ml reaction, the polymerase
chain reaction mastermix consisted of the following: 1ml 10 buffer
(Qiagen, Crawley, UK), 0.2ml dNTPs (10mM; Thermo Scientiﬁc, Northumber-
land, UK), 0.2ml MgCl2 (Thermo Scientiﬁc, UK), 0.1ml HotStarTaq Polymerase
(Qiagen), 1ml IL11 forward primer (Sigma-Aldrich, Poole, UK), 1ml IL11 reverse
primer (Sigma-Aldrich), 2ml DNA and 4.5ml water. Thermal cycling conditions
consisted of an initial enzyme activation stage (95 1C for 10min); followed by
35 cycles of denaturation (95 1C for 30 s), hybridization (58 1C for 30 s) and
extension (72 1C for 1min); and a ﬁnal single-extension step (72 1C for 4min)
and cool-down step (4 1C for 10min).
Controls included both artiﬁcially hypermethylated DNA (positive control)
and RNAse-free water (no template control). Polymerase chain reactions
were performed in duplicate and the products were pooled together to
reduce technical variation. DNA methylation was quantitatively assessed
using the Sequenom EpiTYPER system (Sequenom, San Diego, CA, USA) as
described previously.19 Data generated from the EpiTYPER software were
ﬁltered using in-built quality-control parameters, and CpG units with low call
rates (that is, o90% call rates) were removed.
Statistical analysis
Statistical analyses (i–iii) included age, sex, center of recruitment, baseline
MADRS score and allocated antidepressant drug as covariates. For CpG
units displaying non-normal distributions, we applied the square-root
transformation.
(i) DNA methylation as a predictor of general antidepressant response. To
investigate whether DNA methylation in IL11 could be used as a predictor
of general antidepressant response, we performed univariate linear
regressions with percentage MADRS change as the dependent variable
and CpG unit methylation included as a covariate.
(ii) Differential drug by DNA methylation predictors of antidepressant
response. To assess whether CpG unit methylation might interact with
our two antidepressant drugs to differentially predict an antidepressant
response, we performed univariate linear regressions. Percentage MADRS
change was selected as our dependent variable and covariates included
CpG unit methylation and the interaction between the allocated anti-
depressant drug and the CpG unit methylation.
(iii) DNA methylation rs1126757 predictors of antidepressant response. To
investigate whether there was an interaction between rs1126757 and CpG
unit methylation that could predict antidepressant response, we
performed a univariate linear regression with percentage MADRS change
as the dependent variable, and covariates including rs1126757 genotype,
CpG unit methylation and the interaction between the CpG unit
methylation and rs1126757.
(iv) Multiple testing correction. We entered all P-values generated from
analyses i–iii into a single false discovery rate calculation to generate
q-values. We achieved this using an online false discovery rate web-based
CpG sites:
CpG units:
rs1126757
Gene
SNP
CpG Island
Figure 1. Schematic diagram of interleukin-11 (IL11) in a 50 to 30
direction, with the grey box showing the CpG island our assay
covers and black boxes representing exons (top). Pictogram
representing the individual CpG units within the CpG island, with
black lines noting the CpG units adequately detected by the
Sequenom and grey lines showing CpG units not assessed by this
method (bottom).
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tool available at http://www.sdmproject.com/utilities/?show=FDR. All
q-values p0.1 were considered to be true effects.
(v) Effects of medication, episode duration and recent stressful life events on
DNA methylation. To assess whether previous medication use, the
duration of the current depressive episode or the presence of a recent
stressful life event might be driving any of our false discovery rate-
signiﬁcant predictors, we performed secondary analyses. We performed a
univariate linear regression with CpG unit methylation as the dependent
variable, and use of benzodiazepine, antidepressants, hypnotics and the
presence or absence of a recent stressful life event were included as binary
covariates, with episode duration (weeks) included as a continuous
covariate.
RESULTS
Results from DNA methylation experiments revealed that all
positive controls (hypermethylated DNA) showed greater than
85% detected levels of methylation and all no template controls
(H2O) showed 0% methylation. Eleven out of a possible 18 CpG
units were adequately detected by the Sequenom and passed
quality-control steps (Figure 1). Mean levels of the CpG unit
methylation (%) and standard error (s.e.) at each of the 11 CpG
units can be seen in Figure 2.
DNA methylation as a predictor of general antidepressant
response
A univariate linear regression was performed to assess whether
methylation levels at CpG units in IL11 predicted response to either
antidepressant medication. CpG unit 5 signiﬁcantly predicted
antidepressant response (F¼ 8.429, d.f.¼ 1, Zp2¼ 0.082, P¼ 0.005,
q¼ 0.055; Table 1). Lower levels of DNA methylation at CpG unit 5
was associated with better response to antidepressants (Figure 3).
Differential DNA methylation by drug predictors of antidepressant
response
Univariate linear regressions were performed to assess whether
DNA methylation at any of the CpG units in IL11 acted as a
predictor of differential response. Methylation at CpG unit 4
signiﬁcantly predicted differential response to treatment
(F¼ 8.412, d.f.¼ 1, Zp2¼ 0.083, P¼ 0.005, q¼ 0.055; Table 1). Higher
levels of DNA methylation at CpG unit 4 was associated with
better response in individuals taking escitalopram, but was
associated with worse response in those taking nortriptyline
(Figure 4).
DNA methylation by rs1126757 interaction predictors of
antidepressant response
A univariate linear regression was performed to test whether an
interaction between methylation at any CpG unit and rs1126757
genotype predicted antidepressant response. An interaction
between methylation at CpG unit 11 and rs1126757 signiﬁcantly
predicted response to treatment (F¼ 6.821, d.f.¼ 2, Zp2¼ 0.131,
P¼ 0.002, q¼ 0.055; Table 1). Individuals homozygous for the
G-allele (GG), who had higher levels of methylation at CpG unit 11,
responded better to antidepressant treatment than those
individuals homozygous for the A allele (AA), with no effect of
DNA methylation observed in heterozygotes (AG) (Figure 5).
Testing for confounding factors
Linear regressions revealed that none of our possible confounding
factors (previous medication use, duration of depressive episodes,
or occurrence of a recent stressful life event) were driving DNA
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Figure 2. Bar graph showing mean percentage DNA methylation
in our total sample at each of the 11 CpG units spanning the
interleukin-11 (IL11) CpG island. CpG unit location is shown on the
x-axis and methylation (%) is shown on the y-axis.
Table 1. A summary of the results from the univariate linear regressions
DNA methylation DrugDNA methylation GenotypeDNA methylation
CpG unit F d.f P q F d.f P q F d.f P q
1 0.002 1 0.965 0.966 0.097 1 0.757 0.961 0.784 2 0.459 0.854
2 0.784 1 0.378 0.854 1.672 1 0.199 0.854 0.742 2 0.479 0.854
3 0.058 1 0.810 0.966 0.051 1 0.821 0.966 0.080 2 0.924 0.966
4 1.438 1 0.234 0.854 8.412 1 0.005a 0.055 0.363 2 0.697 0.961
5 8.429 1 0.005a 0.055 2.477 1 0.119 0.854 0.135 2 0.874 0.966
6 0.853 1 0.358 0.854 0.109 1 0.742 0.961 0.034 2 0.966 0.966
7 0.327 1 0.569 0.854 0.327 1 0.569 0.854 0.711 2 0.494 0.854
8 0.407 1 0.525 0.854 0.407 1 0.525 0.854 1.911 2 0.154 0.854
9 0.566 1 0.454 0.854 1.533 1 0.219 0.854 0.594 2 0.554 0.854
10 0.525 1 0.470 0.854 0.525 1 0.470 0.854 0.756 2 0.472 0.854
11 0.010 1 0.920 0.966 0.131 1 0.718 0.961 6.821 2 0.002a 0.055
Results include an F statistic, d.f., P-values and q-values.
A summary of the results from the univariate linear regressions in which we tested whether (from left to right) DNA methylation, drug by DNA methylation
interactions, or rs1126757 genotype by DNA methylation interactions in each of the 11 CpG units could predict antidepressant response. aSignificant P-values
(Pp0.005) are highlighted in bold.
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methylation in any of our three FDR-signiﬁcant DNA methylation
predictors.
DISCUSSION
MDD is becoming an increasing global concern, creating an
urgent need for effective treatment.1,2 With high interindividual
variation in treatment response to antidepressants, the search for
biomarkers aims to personalize therapy and improve upon our
current ‘trial and error’ method of treatment selection.3 Genetic,
proteomic and, recently, transcriptomic biomarker studies have
attempted to identify predictors of antidepressant response, with
varied success.3–8,20 Our previous work identiﬁed a treatment-
emergent expression quantitative trait locus (rs1126757) in IL11,
which predicted response to the antidepressant escitalopram.8
The SNP driving the observed transcriptional differences had
previously been identiﬁed as a predictor of response to
escitalopram as part of a genome-wide association study.4,8
Subsequently, we hypothesized that other baseline factors with
the potential to affect transcription factor binding and gene
expression changes in IL11 might also predict antidepressant
response. Here we explored the potential utility of DNA
methylation in IL11 as a baseline predictor of antidepressant
response.
The results detailed here are the ﬁrst to demonstrate the
potential use of pharmaco-epigenetic biomarkers as the baseline
predictors of antidepressant response. Our results suggest that
CpG unit-speciﬁc DNA methylation in IL11 could be used to
predict whether an individual is likely to respond to antidepres-
sants (see Figure 3) and, if they are, the type of drug best suited to
each individual (see Figure 4). The interaction between genotype
and DNA methylation also reveals the importance of integrating
genotype and methylation data in search of molecular biomarkers
for antidepressant response (see Figure 5).
IL11 has previously been found to induce potent inhibitory
effects on serotonin signaling.21 Consequently, it adds to a grow-
ing number of functionally relevant cytokines, which have been
previously associated with antidepressant response (for example,
tumor necrosis factor and IL-6).4,8,20,22 It also further supports
suggestions that augmentation therapies targeting the cytokines
might be useful in improving response to antidepressants.23–25
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Figure 3. Scatter plot of the relationship between DNA methylation
at CpG unit 5 (x-axis) and percentage Montgomery-Åsberg Depres-
sion Rating Scale (MADRS) change (y-axis). Line represents the line
of best fit. DNA methylation at CpG unit 5 significantly predicted
percentage MADRS change in our model (P¼ 0.005).
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Figure 4. Scatter plot of the relationship between percentage
DNA methylation at CpG unit 4 (x-axis) and percentage Montgom-
ery-Åsberg Depression Rating Scale (MADRS) change (y-axis).
Lines represent line of best fit for each drug group. DNA methyl-
ation at CpG unit 4 was found to significantly interact with the
drug type to predict percentage MADRS change in our model
(P¼ 0.005).
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Figure 5. Scatter plot of the relationship between percentage DNA
methylation at CpG unit 11 (x-axis) and percentage Montgomery-
Åsberg Depression Rating Scale (MADRS) change (y-axis). Data
points and lines of best fit correspond to different genotypes of the
genome-wide association study single-nucleotide polymorphism,
rs1126757. DNA methylation at CpG unit 11 was found to
significantly interact with rs1126757 to predict percentage MADRS
change in our model (P¼ 0.002).
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The cause of our observed DNA methylation differences
remains unclear, but based on our results they are unlikely to
be related to episode duration, current medication use or
experiences of a recent stressful life event. In future studies, it
would be interesting to test whether early stressful life events
might predict DNA methylation in IL11, as early life stressors are
known modulators of the methylome, affect the levels of
inﬂammatory markers and act as a risk factor for MDD.26–29
Despite the promising results detailed here, the study has three
main limitations. First, the differences in DNA methylation
observed are small and CpG unit-speciﬁc; hence, further studies
are required to determine whether these differences are
biologically meaningful. Second, although blood has useful
biomarker properties (e.g., it is renewable, peripherally accessible
and has access to the brain tissue), further work is still required to
understand how DNA methylation differences in the blood might
relate to the differences in the brain. Third, our method could not
detect DNA methylation at all CpG sites, and in some cases it
used averages across neighboring CpG sites to form CpG units
(see Figure 1).
In conclusion, results presented here are the ﬁrst to demon-
strate the potential clinical utility of DNA methylation biomarkers
as predictors of antidepressant response. Future studies are
further needed to replicate these ﬁndings and validate the
relationship between site-speciﬁc methylation in IL11 and
antidepressant response.
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